Dyne Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDDyne Therapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 85), indicating clear outperformance against the broad market. Earnings growth of 30% provides fundamental context to the price action. However, price is extended 27% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $20.12 | +18.45% | ABOVE |
| 50 SMA | $18.75 | +27.10% | ABOVE |
| 100 SMA | $18.18 | +31.10% | ABOVE |
| 150 SMA | $18.37 | +29.75% | ABOVE |
| 200 SMA | $18.13 | +31.45% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is DYN in an uptrend right now?
DYN has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is DYN overbought or oversold?
DYN's RSI (14) is 69. The stock is in neutral territory, neither overbought nor oversold.
Is DYN outperforming the market?
DYN has a Relative Strength (RS) Rating of 85 out of 99. Yes, DYN is a market leader, outperforming 85% of all stocks over the past 12 months.
Where is DYN in its 52-week range?
DYN is trading at $23.83, which is 95% of its 52-week high ($25.00) and 93% above its 52-week low ($8.24).
How volatile is DYN?
DYN has a Beta of 2.15 and 52-week volatility of 80%. It's more volatile than the S&P 500 - expect bigger swings.